GlassScriptPhysician profile
Christopher Esworthy
NPI 1710515085
$30,516.64
in general payments reported to CMS, 2019-2025
51 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,184 · 2022: $1,951 · 2023: $2,990 · 2024: $12K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $8,846 · Travel and Lodging: $3,871 · Consulting Fee: $580 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,072.50 |
| Food and Beverage | $8,845.88 |
| Travel and Lodging | $3,870.58 |
| Consulting Fee | $580.00 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $20,056.10 | 2021-2025 | Descovy, Yeztugo, Biktarvy |
| Abbvie INC. | $3,218.52 | 2021-2025 | |
| Novo Nordisk INC | $2,030.01 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $556.57 | 2021-2025 | |
| Viiv Healthcare Company | $514.16 | 2022-2025 | Apretude |
| Takeda Pharmaceuticals U.S.A., INC. | $423.94 | 2021-2025 | Trintellix, Cuvitru |
| Neos Therapeutics, LP | $273.40 | 2021-2025 | Adzenys Xr-Odt |
| Astrazeneca Pharmaceuticals LP | $272.18 | 2023-2025 | Airsupra, Fasenra, Breztri |
| Janssen Pharmaceuticals, INC | $255.39 | 2023 | Xarelto |
| Lilly USA, LLC | $223.32 | 2021-2025 | Mounjaro, Emgality |
| Amgen INC. | $221.84 | 2021-2023 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $212.70 | 2023 | Quviviq |
| Corium, LLC | $208.29 | 2023-2024 | Azstarys |
| Incyte Corporation | $196.08 | 2022-2024 | Opzelura |
| Glaxosmithkline, LLC. | $174.52 | 2021-2023 | Shingrix, Arexvy |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Esworthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.